Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

British journal of pharmacology - 1 Aug 2012

Ancrenaz V, Desmeules J, James R, Fontana P, Reny J-L, Dayer P, Daali Y

Abstract excerpt

BACKGROUND AND PURPOSE: Clopidogrel is a prodrug bioactivated by cytochrome P450s (CYPs). More recently, paraoxonase-1 (PON1) has been proposed as a major contributor to clopidogrel metabolism. The purpose of this study was to assess the relative contribution of CYPs and PON1 to clopidogrel metabolism in vitro. EXPERIMENTAL APPROACH: Clopidogrel metabolism was studied in human serum, recombinant PON1 enzyme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryldialkylphosphatase
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Microsomes

Share to Microsomes, Liver

Share to Molecular Structure

Share to Tandem Mass Spectrometry

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 22428615
DOI: 10.1111/j.1476-5381.2012.01946.x
PMCID: PMC3448899

Genes

PON1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.PMID 22428615Read ↗

Pharmacogenomics of clopidogrel: evidence and perspectives.Semantic proximity Read ↗

Paraoxonase-1 is a major determinant of clopidogrel efficacy.Semantic proximity Read ↗

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.Semantic proximity Read ↗

Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.Semantic proximity Read ↗

Unveiling the mysteries of clopidogrel metabolism and efficacy.Semantic proximity Read ↗

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.Semantic proximity Read ↗

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.Semantic proximity Read ↗

Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.Semantic proximity Read ↗

The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.Semantic proximity Read ↗

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.Semantic proximity Read ↗

Current controversies in the pharmacogenomics of clopidogrel.Semantic proximity Read ↗

The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.